Literature DB >> 9507929

Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil.

T M Engber1, E J Koury, S A Dennis, M S Miller, P C Contreras, R V Bhat.   

Abstract

We examined the neuronal targets in the rat brain for the novel wakefulness-promoting agent modafinil and for amphetamine using c-Fos immunohistochemistry. Both modafinil and amphetamine induced neuronal expression of c-Fos-like immunoreactivity in the paraventricular nucleus of the hypothalamus, anterior hypothalamus and central nucleus of the amygdala. Modafinil also increased c-Fos-like immunoreactivity in the suprachiasmatic nucleus, while amphetamine had no effect. Brain regions in which amphetamine increased c-Fos-like immunoreactivity, but modafinil had no effect, included frontal cortex, striatum, lateral habenula, supraoptic nucleus and basolateral nucleus of the amygdala. These findings suggest that the mechanism of action of modafinil is different from that of amphetamine and that the neuronal targets for modafinil in the brain include nuclei of the hypothalamus and amygdala.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9507929     DOI: 10.1016/s0304-3940(97)00962-2

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  32 in total

Review 1.  Narcolepsy in children: a practical guide to its diagnosis, treatment and follow-up.

Authors:  C Guilleminault; R Pelayo
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

2.  Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs.

Authors:  B E H Sumner; L A Cruise; D A Slattery; D R Hill; M Shahid; B Henry
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

3.  Effect of modafinil on impairments in neurobehavioral performance and learning associated with extended wakefulness and circadian misalignment.

Authors:  Scott Grady; Daniel Aeschbach; Kenneth P Wright; Charles A Czeisler
Journal:  Neuropsychopharmacology       Date:  2010-05-26       Impact factor: 7.853

4.  Modafinil in sports: ethical considerations.

Authors:  K R Kaufman
Journal:  Br J Sports Med       Date:  2005-04       Impact factor: 13.800

5.  Stress modulation of the memory retrograde-enhancing effects of the awakening drug modafinil in mice.

Authors:  Daniel Béracochéa; Pierrette Liscia; Christophe Tronche; Frédéric Chauveau; Jean-Claude Jouanin; Christophe Piérard
Journal:  Psychopharmacology (Berl)       Date:  2007-10-13       Impact factor: 4.530

6.  Environmental novelty differentially affects c-fos mRNA expression induced by amphetamine or cocaine in subregions of the bed nucleus of the stria terminalis and amygdala.

Authors:  H E Day; A Badiani; J M Uslaner; M M Oates; N M Vittoz; T E Robinson; S J Watson; H Akil
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

Review 7.  Modafinil : a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder.

Authors:  Gillian M Keating; Michael J Raffin
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

8.  Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: an open-label safety study assessing three strategies.

Authors:  Michael J Thorpy; Jonathan R L Schwartz; Ruzica Kovacevic-Ristanovic; Roza Hayduk
Journal:  Psychopharmacology (Berl)       Date:  2003-04-23       Impact factor: 4.530

9.  Acute effects of light on the brain and behavior of diurnal Arvicanthis niloticus and nocturnal Mus musculus.

Authors:  Dorela D Shuboni; Shannon L Cramm; Lily Yan; Chidambaram Ramanathan; Breyanna L Cavanaugh; Antonio A Nunez; Laura Smale
Journal:  Physiol Behav       Date:  2014-10-28

10.  Behavioral responses of dopamine beta-hydroxylase knockout mice to modafinil suggest a dual noradrenergic-dopaminergic mechanism of action.

Authors:  Heather A Mitchell; James W Bogenpohl; L Cameron Liles; Michael P Epstein; Donna Bozyczko-Coyne; Michael Williams; David Weinshenker
Journal:  Pharmacol Biochem Behav       Date:  2008-07-25       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.